Corrigan will lead global direction and oversight of CRO’s quality and compliance programs
Research Triangle Park, N.C. – May 3, 2022 – Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), announced that Rosemarie Corrigan has joined the company as executive vice president, global quality.
Today’s pharmaceutical regulatory environment is dynamic and accelerating – a continuous flow of changing requirements that makes it necessary for research organizations to constantly anticipate and evolve quality and compliance standards. Worldwide expects regulatory developments and actively plans for them in the compliance process. Corrigan’s experience builds upon this foundation, spanning more than two decades of diverse GxP (good practice) experience in quality assurance (QA) leadership roles in biotechnology, pharmaceutical, and contract research organizations, from product life cycle to discovery. As executive vice president, global quality, she will leverage her experience to lead the global direction and oversight of the organization’s quality and compliance programs.
“At Worldwide, our sponsors count on our rigorous study conduct and time-tested, fit-for-purpose methodologies that ensure data quality. That’s why Rosemarie’s experience makes her a vital addition to our team,” said Peter Benton, president and co-CEO, Worldwide. “As a recognized industry leader with more than 25 years of biotech and pharma experience, Rosemarie will provide sage strategic leadership to our organization at a time when the clinical trials industry is beset with new challenges – from real-world data implications and diversity and inclusion to supply chain and rebuilding patient trust globally. We’re proud to welcome her to our growing team.”
Corrigan’s vast experience includes leadership positions in both small and large organizations, including most recently as chief quality officer at Nordic Nanovector, where she established QA strategy and operations for development of radiopharmaceutical products. She also served as global head of QA at Oxurion NV (previously Thrombogenic NV), supporting its products through development, launch, and commercialization. Prior to that, as executive director of Stiefel Laboratories Inc. (now part of GSK), she was responsible for global R&D QA and compliance.
Corrigan earned a masters in bioethics and medical law from St Mary’s University, London, and a Bachelor of Science in biochemistry from University College Galway. She is an active member of the Research Quality Association’s GCP Committee and its current chair, as well as an EU Qualified Person (QP) for Investigational Medicinal Products.
For Worldwide, QA is focused on compliance, protection, and safety of subjects and the integrity of clinical trial data. In the most recent ISR Report, Worldwide outperformed other CROs for Phase I-III trials across the board, earning specific top-performer rankings for data quality, as well as project management quality, responsiveness, patient recruitment, and budget factors. Learn more about Worldwide’s industry-recognized quality assurance protocols here.
About Worldwide Clinical Trials:
Worldwide Clinical Trials is a global, midsize contract research organization (CRO) that provides top-performing preclinical and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries.
Founded in 1986 by physicians committed to advancing medical science, our full-service clinical experience ranges from early phase and bioanalytical sciences through late phase studies, post approval, and real-world evidence. Major therapeutic areas of focus include cardiovascular, metabolic, neuroscience, oncology, and rare diseases. With infrastructure spanning 60 countries and offices in North and South America, Eastern and Western Europe, and Asia, Worldwide is powered by its more than 3,000 employee experts.
Worldwide Clinical Trials
VP, Global Corporate Communications